Next-generation therapeutic solutions for age-related macular degeneration
| Autor: | Shusheng Wang, Rafael Ufret-Vincenty, Khrishen Cunnusamy |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Vascular Endothelial Growth Factor A
Pathology medicine.medical_specialty Visual acuity genetic structures Angiogenesis Inhibitors Disease Vascular leakage Blindness Bioinformatics Neuroprotection Article Patents as Topic Macular Degeneration Age related Animals Humans Medicine Aged business.industry General Medicine Macular degeneration medicine.disease eye diseases Choroidal neovascularization Drug Design sense organs medicine.symptom business |
| Zdroj: | Pharmaceutical Patent Analyst. 1:193-206 |
| ISSN: | 2046-8962 2046-8954 |
| DOI: | 10.4155/ppa.12.12 |
| Popis: | Age-related macular degeneration (AMD) is the primary cause of blindness among the elderly worldwide. To date, no cure is available, and the available palliative treatments only showed limited efficacy in improving visual acuity. The etiology of AMD remains elusive but research over the past decade has uncovered characteristic features of the disease. Known as the hallmarks of AMD, these features include (A) oxidative stress and RPE cytotoxicity; (B) loss of macromolecular permeability and hydraulic conductivity: (C) inflammation; (D) choroidal neovascularization and vascular leakage; and (E) loss of neuroprotection. Recent breakthrough in understanding the pathogenesis of AMD has spawned an array of novel therapeutic agents designed to address these hallmarks. Here we review the features of AMD and highlight the most promising therapeutic and diagnostic approaches based on the patents published from 2008 to 2011. Most likely, a next generation treatment for AMD will be developed from these emerging efforts. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|